Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1434207

	registered interest
	date	22/02/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Government's response to the Health and Social Care Select Committee’s report on Drugs Policy: Medicinal Cannabis, published in September 2019, what steps his Department has taken with the National Institute for Health Research to develop alternative research approaches to support children who are currently receiving cannabis-based products for medicinal use rather than randomised control trials, as set out in that response.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	127511
	answer	answer is ministerial correction date of answer 25/02/2022 answer text <p>Research funding can be accessed through applications to the National Institute for Health Research (NIHR). The NIHR relies on researchers submitting high-quality applications and welcomes research proposals to evaluate the safety and clinical efficacy of cannabis-based products for medicinal use. The NIHR and the Medicines and Healthcare products Regulatory Agency (MHRA) will consider novel trial designs and it is not a specific requirement to conduct double blind trials. The MHRA has recently published guidance on the use of real-world data in clinical studies to support regulatory decisions.</p><p>The NIHR and the National Health Service will be supporting two randomised controlled trials into epilepsy. Alternative research approaches, such as an observational study, were considered in the trial design but discounted as it would not produce robust results nor add to the current evidence base.</p><p>In 2018, NHS England asked the British Paediatric Neurology Association (BPNA) to develop interim guidance for clinicians in the use and prescription of cannabis‐based products for medicinal use in children and young people with epilepsy. The National Institute for Health and Care Excellence (NICE) then published guidelines covering prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. The BPNA has subsequently updated their guidance. As with all decisions to prescribe medicines, the General Medical Council expects doctors to use their professional judgement when deciding to what extent any clinical guidance is relevant.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 127512 127513 question first answered 25/02/2022 14:51:45 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4623 label Biography information for Tonia Antoniazzi

1434209

	registered interest
	date	22/02/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Government response to the Health and Social Care Select Committee’s report on Medicinal Cannabis in September 2019, what plans he has to ensure that the role of guidance from the BPNA relating to medical cannabis is replaced by the recently published guidance by NICE.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	127512
	answer	answer is ministerial correction date of answer 25/02/2022 answer text <p>Research funding can be accessed through applications to the National Institute for Health Research (NIHR). The NIHR relies on researchers submitting high-quality applications and welcomes research proposals to evaluate the safety and clinical efficacy of cannabis-based products for medicinal use. The NIHR and the Medicines and Healthcare products Regulatory Agency (MHRA) will consider novel trial designs and it is not a specific requirement to conduct double blind trials. The MHRA has recently published guidance on the use of real-world data in clinical studies to support regulatory decisions.</p><p>The NIHR and the National Health Service will be supporting two randomised controlled trials into epilepsy. Alternative research approaches, such as an observational study, were considered in the trial design but discounted as it would not produce robust results nor add to the current evidence base.</p><p>In 2018, NHS England asked the British Paediatric Neurology Association (BPNA) to develop interim guidance for clinicians in the use and prescription of cannabis‐based products for medicinal use in children and young people with epilepsy. The National Institute for Health and Care Excellence (NICE) then published guidelines covering prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. The BPNA has subsequently updated their guidance. As with all decisions to prescribe medicines, the General Medical Council expects doctors to use their professional judgement when deciding to what extent any clinical guidance is relevant.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 127511 127513 question first answered 25/02/2022 14:51:45 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4623 label Biography information for Tonia Antoniazzi

1271721

	registered interest
	date	16/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of children who currently have their UK prescriptions for medical cannabis dispensed in the Netherlands; and if he will make a statement.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	130805
	answer	answer is ministerial correction date of answer 12/02/2021 answer text <p>From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.</p><p>The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.</p><p>The Written Ministerial Statement of 26 January (<a href="https://questions-statements.parliament.uk/written-statements/detail/2021-01-26/hcws734" target="_blank">HCWS734</a>) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 130806 130807 130808 130809 130810 question first answered 12/02/2021 10:03:33 answering member 4380 label Biography information for Jo Churchill previous answer version 72730 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4623 label Biography information for Tonia Antoniazzi

1271722

	registered interest
	date	16/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that children who currently have their UK prescriptions for medical cannabis dispensed in the Netherlands will still be able to receive their medicine at the end of the transition period; and if he will make a statement.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	130806
	answer	answer is ministerial correction date of answer 12/02/2021 answer text <p>From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.</p><p>The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.</p><p>The Written Ministerial Statement of 26 January (<a href="https://questions-statements.parliament.uk/written-statements/detail/2021-01-26/hcws734" target="_blank">HCWS734</a>) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 130805 130807 130808 130809 130810 question first answered 12/02/2021 10:03:33 answering member 4380 label Biography information for Jo Churchill
	tabling member	4623 label Biography information for Tonia Antoniazzi

1271723

	registered interest
	date	16/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions (a) he and (b) his officials have had with (i) patients, (ii) patient groups, (iii) special import pharmacies and (iv) prescribing clinicians on the ability to switch at short notice between different medical cannabis products; and if he will make a statement.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	130807
	answer	answer is ministerial correction date of answer 12/02/2021 answer text <p>From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.</p><p>The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.</p><p>The Written Ministerial Statement of 26 January (<a href="https://questions-statements.parliament.uk/written-statements/detail/2021-01-26/hcws734" target="_blank">HCWS734</a>) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 130805 130806 130808 130809 130810 question first answered 12/02/2021 10:03:33 answering member 4380 label Biography information for Jo Churchill previous answer version 72731 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4623 label Biography information for Tonia Antoniazzi

1271725

	registered interest
	date	16/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that children who have their UK prescriptions for medical cannabis dispensed in the Netherlands will continue to receive their medicine after the transition period; and if he will make a statement.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	130808
	answer	answer is ministerial correction date of answer 12/02/2021 answer text <p>From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.</p><p>The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.</p><p>The Written Ministerial Statement of 26 January (<a href="https://questions-statements.parliament.uk/written-statements/detail/2021-01-26/hcws734" target="_blank">HCWS734</a>) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 130805 130806 130807 130809 130810 question first answered 12/02/2021 10:03:33 answering member 4380 label Biography information for Jo Churchill previous answer version 72732 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4623 label Biography information for Tonia Antoniazzi

1271726

	registered interest
	date	16/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether children in Northern Ireland will be able to have their UK prescriptions for medical cannabis dispensed in the Netherlands after the transition period; and if he will make a statement.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	130809
	answer	answer is ministerial correction date of answer 12/02/2021 answer text <p>From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.</p><p>The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.</p><p>The Written Ministerial Statement of 26 January (<a href="https://questions-statements.parliament.uk/written-statements/detail/2021-01-26/hcws734" target="_blank">HCWS734</a>) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 130805 130806 130807 130808 130810 question first answered 12/02/2021 10:03:33 answering member 4380 label Biography information for Jo Churchill previous answer version 72733 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4623 label Biography information for Tonia Antoniazzi

1271727

	registered interest
	date	16/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Dutch Government on lifting their ban on the export of finished medical cannabis oils; and if he will make a statement.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	130810
	answer	answer is ministerial correction date of answer 12/02/2021 answer text <p>From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.</p><p>The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.</p><p>The Written Ministerial Statement of 26 January (<a href="https://questions-statements.parliament.uk/written-statements/detail/2021-01-26/hcws734" target="_blank">HCWS734</a>) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 130805 130806 130807 130808 130809 question first answered 12/02/2021 10:03:33 answering member 4380 label Biography information for Jo Churchill previous answer version 72734 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4623 label Biography information for Tonia Antoniazzi

1166773

	registered interest
	date	28/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answers of 27 June 2019 to Questions 266861 and 266862, how many prescriptions for full-extract medical cannabis have been fulfilled by the NHS since November 2018.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	6489
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Dissolution.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 05/11/2019 16:56:36 answering member 4380 label Biography information for Jo Churchill
	tabling member	4623 label Biography information for Tonia Antoniazzi

1166774

	registered interest
	date	28/10/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what the Government’s policy is on the importation of small amounts of prescribed medical cannabis that have been sourced from abroad.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	6490
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p><strong><em>It has not proved possible to respond to the hon. Member in the time available before Dissolution.</em></strong></p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 05/11/2019 17:02:31 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4623 label Biography information for Tonia Antoniazzi